¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º N 4,w  
$1UN?(r  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ , :kCt=4%  
VDQ&Bm JE  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) ][0HJG{{g  
@];Xbbw+c  
1. ICAM-1 J/ rQ42d  
vmmu[v  
2. interleukin 12(IL-12) iAXx`>}m  
dn`#N^Od  
3. tumor infiltrating lymphocyte B"{CWH O  
~%sDQt\S  
4. TCR/CD3 complex ^(6.P)$  
geT<vh Z6  
5. hematopoietin receptor family guf+AVPno  
y6G[-?"/Q  
6. individual idiotype(IdI) cvc.-7IO  
,',fO?Qv'  
7. integrin ^TB%| yZ _  
)_f "[m%  
8. colony-stimulatory factor (CSF) \WZ00Y,*  
>r{,$)H0  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£©  ^mG-O  
R':a,6 O  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? +n%WmRf6!  
&;C|=8eB  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ ;1F3.ibE  
k deJB-  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠTNiF l hq  
"esV#%:#J  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ t1Cyyb  
Ak|j J  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) 9/Q5(P  
\t )Zk2  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ *y.KD4@{  
Hh;7 hY\  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) 9I.="b=J)  
"rkP@ja9n  
3. immunoglobulin superfamily (IgSF) ?;}2 Z)  
oST Gs@EK  
4. selectin z^=9 %tLJ  
3<?(1kSo>>  
5. anti-idiotypic antibody (¦ÁId) M-0BQs`N  
?l bK;Kv  
6. major histocompatibility complex(MHC) |8V+(V zl  
-YRF^72+  
7. immunotolerance V"\t  
R%54!f0 %  
8. biological reponse modifier(BRM) 7pr@aA"vgj  
C#vU'RNpl  
9. immune reponse gene (Ir gene) CA:t](xqQ  
FRX'"gIR0  
10. reshaped antibody (or reconstituted antibody) Y+j|T`d  
JAc-5e4  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© o3j4XrK  
E3sl"d;~  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ >`\~=ivrD  
-bcm"(<T'  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? t"JfqD E  
|a/"7B|?\  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ *|ubH?71%Y  
%A:<rO85o  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? 2NqlE  
->$Do$  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ l>H#\MR  
-h8A<  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? E0Ig/ j  
9;sebqC?  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ D3|y|Dr  
68W&qzw.[r  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ F@)wi0  
7S(5\9  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? ,*wa#[  
%9uLxC;  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ }&bO;o&>  
QI.{M$,m~  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: 6;"jq92in*  
&r;-=ASYzV  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: _>S."cm}!k  
:Fm;0R@/k  
ÃâÒßѧ 'n6D3Vse  
 Fr`"XH  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© #kR8v[Z  
,Hlbl}.ls  
1. CD8 Y1h8O%?  
+Vl\lL -  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) Cd?a C  
96fbMP+7R  
3. immunoglobulin fold(Ig fold) A9`& Wnw?  
( d#E16y  
4. cadherin (Ca-dependent cell adhesion moleculers) BGh1hyJ8d  
iO4Yfj#?  
5. idiotype-anti-idiotypic antibody immune network theory k?zw4S  
k)U9 %Pr  
6. HLA class II antigen Q`j!$r  
F%Oy4*4  
7. complementarity-determining region (CDR) (S3\O `5  
TmZ sC5  
8. perforin(or pore-forming protein ,PFP) o/I'Qi$v-  
&Azfpv   
9. high affinity IL-2 receptor DyhW_PH2J  
Ac{"$P`  
10. artificial active immunization $o2H#"  
eb&#sZ  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© cih[A2lp  
!6.}{6b  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠY<0}z>^  
moz*=a  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 PggjuPPh  
4k%y*L  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ L{PH8Xl_  
s9^r[l@W0U  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ B'[FnJ8~  
1j4tR#L  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ % \N52  
l5; SY  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? :]]#X ~J  
f)'m pp^  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ $>if@}u  
f%ThS42  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ ^W8kt  
vU(uu:U9  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ) oypl+y  
z.d1>w  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ ' v)@K0P  
H<N$z 3k  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© HgY [Q}7s  
tRC*@>I$  
1. immunoglobulin gene rearrangement vIzREu|5  
gPT<%F  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) B r`a;y T  
3:]c>GPQ  
3. flow cytometry(FCM) nXRT%[o &  
),!1B%  
4. carrier effect WWBm*?U  
\-`,fat  
5. positive selection of T lymphocytes in thymus Py72:;wn  
#];b+ T  
6. mouse TH1(Th1) and TH2(Th2) subsets @'AjEl:&-_  
a]S0|\BkN  
7. perforin (pore-forming protein ,PFP) *r90IS}A$2  
-xVp}RLT  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) P$7i>(?(  
L ^E#"f  
9. SH-2(src-homology region 2) T1~G {@"  
DWwPid} "  
10. Ab2¦Â (internal image) 7{ JIHY+  
`m")v0n3  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© `qs[a}%'>"  
G2y`yg  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? ud grZ/w]  
\ 9!hg(-F  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? 2 ":W^P  
b2r]>*Vc  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠDa3Z>/S  
"xdu h3/~=  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ =pk5'hBAi  
X/BcS[a  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠmDdL7I  
4K(oOxc9.  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) ]8+ D  
E (.~[-K4  
ÃâÒßѧרҵ£º I83 _x|$FZ  
dRL*TT0NW  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ OpD%lRl  
(jp!q ,)  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? vdaG?+_o  
"&%Lhyt  
´«È¾²¡Ñ§×¨Òµ£º H8!)zZ  
&V(;zy4(R  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ Wl0p-h  
/T<))@$  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ ( yK@(euG  
I~F]e|Ehqr  
Ïû»¯×¨Òµ£º gwyX %9  
BZOB\Ym  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ AL{iQxQ6  
-q30tO.  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? }eAV8LU  
"F:V$,mJ  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ {,B. OM)J  
7{lWg x  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 2jF}n*[OW  
VDFs.;:s  
1. Fas(CD95)/FasL 1hY%Zsj C  
wx8Qz,Z  
2. common chain of cytokine receptor  WH_ W:  
>rXDLj-e  
3 . TCR/CD3 complex HX{K5+  
g(C/J9J  
4. negaive selection of thymocytes T3NH8nH9"z  
jqlfypU  
5. artificial active immune 7J1f$5$m5  
$ {e5Ka  
6. anti-idiotypic M(1cf(<+  
AC*SmQ\>!  
7. IgSF wf_ $#.;m  
"R\D:Olb#  
8. Integrin 2UG>(R:  
pVM1%n:#  
9. chemokine _*cKu>,O  
vdh[%T,&  
10. B7/CD28 =z TpDL  
,Jx.Kj.,  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© w"O{@2B3:H  
 1vYa&!  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ T$sm}=  
p|em_!H"SH  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ SmAii}-jf  
@; tM R|p  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ X|yVRQ?F`  
FOh q&\nkU  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ $b[Ha{9(v  
/A+5q\8G  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ -q(*)N5.2  
FOteN QTj  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ #ro$$I;  
5LZs_%#  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 4,f`C0>"  
D< kf/hj  
1. B7/CD28 ]E)D})r`#  
7j HrLsB  
2. Th1 subset NV==[$(r  
#M<YNuE#"  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© ^ Nu j/  
ysCK_  
4. antibody affinity maturation Igw2n{})w  
DL d~  
5. AP-1  M`7[hr  
DMTc{  
6. single chain variable fragment£¨ScFv£© C+>mehDC_G  
8C[eHC*r  
7. NK cell receptor H/k]u)Gtv  
stMxlG"d  
8. Zinkernagel-Doherty phenomenon vE1:;%Q  
(pHJEY  
9. Ig fold Ups0Xg&{  
'+ mI  
10. CD40/CD40L feH&Ug4?G  
nf[KD,f  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© epG]$T![  
-0BxZ AW=  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ 2^"! p;WQ  
j+S&5C/{  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ }D`ZWTjDay  
>;F}>_i  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ x>,wmk5)  
S4c- i2Rq  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ ?"T!<L  
t:P7ah  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ j?T>S]xOX  
}eI9me@Aa  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ mkPqxzxbrL  
W#kyD)(F  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ #%8)'=1+4?  
("{vbs$;  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© b|G~0[g  
t;0]d7ey'  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© +2k{y l  
Hw toa,  
1.Co-stimulators (or co-stimulating molecules) Cs,Cb2[  
H 3pZfdh?w  
2.NK-kB 9b&;4Yq!f  
&~x|w6M]J  
3.Immunoglobulin superfamily 6' \M:'<0e  
U#sv.r/L}3  
4.antigen-presenting cell (APC) ?B)e8i<[f  
(&V)D?/hS  
5.death domain cVarvueS  
qlg.\H:W~  
6.CCR and CXCR ()$m9%x  
09 f;z  
7.Lectin (or mitogen) tu@-+< *  
(KfQ'B+  
8.Clusters of differentiation, CD) uINEq{yo  
iCGHcN^3  
9.B7 family P1]F 0fR  
J-G)mvkv  
10.Cytotoxic T lymphocyte, CTL) v}z^M_eFm  
Y{@foIZ  
11.IL-15 and IL-15 receptor (IL-15R) 0C"2?etMx  
.vIRz-S  
12.MHC restriction vfVF^ WOd  
'!4\H"t  
13.Affinity-chromatography EpCNp FQT<  
V1,~GpNx  
14.Cyctosprin A, CsA nDLiER;U  
?i!d00X  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC)  ;Yg/y  
dDA&\BuS  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© G[fg!vig#7  
Y9%zo~]-W'  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 <K/iX%b?  
!HW?/-\,O  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ MRK3Cey}%  
u)/i$N  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ KEq48+j  
)sK _k U{\  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© &s\/Uq  
g`"_+x'  
ÃâÒßѧרҵ£º 9om}j  
S6_dmTV*  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ hsI9{j]f  
C6D Eq>v  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ `{}DLaD9  
SuBUhzR  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ H^$7=  
Of<Vr.m{R  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) RNcnE1=  
_M- PF$  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) S9qc34\^=  
VlxHZ  
1. ADCC(antibody dependent cell-mediated cytotoxicity) UGA` `;f  
bHz H0v]:  
2. »·æß¾úËØ(cyclosporin) @4]dv> Z  
IBh?vh  
3. KIR(killer cell inhibitory receptor) &Z7NF|  
8Tp!b %2.  
4. HLDA(human leucocyte differentiation antigen) AUr~b3< 6  
{9nH#yv  
5. Interleukin 18(IL-18) ):5H,B+Vr&  
x J\>;$CY  
6. ÕûºÏËØ(integrin) D<bH RtP  
/nNrvMt v  
7. Fas/FasL Tpp?(lT7r  
kfkcaj4l]  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) 7KV0g1GQ  
xG,L*3c{o  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) zj#8@gbh+  
Q::_i"?c  
10. Th1/Th2 JP6+h>ft  
KhNO xMZ  
11. »ùÒòÒßÃç(DNAÒßÃç) Z$Vd8U;  
XWf1c ~J  
12. chemokines and chemokine receptor $1bzsB|^  
<;zcz[~  
13. ÃâÒßÄÍÊÜ tP|ox]  
_4X3g%nXl  
14. ¹²´Ì¼¤·Ö×Ó H>|*D~RdT  
/jd.<r=_I  
15. ËÀÍö½á¹¹Óò(death domain) 4inM d![  
x^6b$>1  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) ~L=? F  
(aSY.#;  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? ]+@I] \S4  
^<+V[ =X  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠn_P2l<F~/x  
xC-&<s  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î &K-0ld(;  
\@GKVssw  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ qnTW?c9Z5  
VK^m]??s_  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå #0 eop>O  
asKAHVT(  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ Yjh02wo  
lD@`xq.M;  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) 2#xz,RM.  
O <"\G!y~  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ 0E/,l``p  
4-~S"T8<u  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ H.*aVb$  
2HF_kYZ  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»